RWF_CA209-436

A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)

This is a signaling study to assess whether nivolumab in combination with brentuximab vedotin is safe and effective in certain subtypes of non-hodgkin lymphomas.

Inclusion Criteria:

•Relapsed/refractory diffuse large B cell lymphoma(DLBCL),relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma) and relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS)

•Expression of CD30

Exclusion Criteria:

•Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy

•Active, known, or suspected autoimmune disease
Phase I/II
NCT02581631
Cancer, All Other
Hematologic
John Godwin, M.D.
BMS (Bristol-Myers Squibb)
Laurie Delanty
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Westside